



Solo 2

ENGOT-OV21

Study of O^Loparib in O^Varrian Cancer

A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy



PRIMARY OBJECTIVE ANALYSIS

- ▶ **Database Lock on October 19th 2016**
- ▶ **Results to be presented to SOLO-2 Steering Committee after the Lisbon meeting**